Only around 20% of eligible US patients currently receive CAR-T therapy. Drawing on the Cell & Gene Therapy Insights CAR-T Special Interest Group, this infographic examines the manufacturing barriers behind that gap and compares three routes to wider access: autologous, allogeneic, and in vivo CAR-T.
No takes yet. Share an insight, caveat, or question.
no authors (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: